本帖最后由 maicon08 于 2023-4-28 15:12 编辑
; e$ j5 k* I5 k2 W* }, N- O5 @/ V, k/ h) o
一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。6 j. t) T A" b- g) }+ j* k' M
. z# _) G: A. f% h
https://www.163.com/dy/article/I3BTTPRD053438SI.html Q% f+ Z* n2 U( r* n% X) g8 n* D0 v1 `' ^
0 F$ e z+ R/ H. |( W1 ]: _; J" z' C
. g0 {/ @) Z0 Z; l在研疗法-免疫治疗: v5 t0 ~# b. {+ s
Developmental Therapeutics—Immunotherapy$ y- H( I& T9 F/ Y0 ^
# Z, A) ^- W. { }0 k. m摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心
: F9 |# ]+ k5 x' D; k# M
在研疗法-分子靶向药物和肿瘤生物学6 V5 O! ?5 m- N, u9 c/ `4 X
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology 3 N: G+ q( v' N, K% S( y
摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心
4 D" `7 ?% b" d4 u
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院 $ `* b9 j8 x d
胃肠道肿瘤-结直肠癌和肛门癌
' H: q6 n# ~; X$ X7 Y; V* ^" ? Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院
7 W* |0 y# j' N0 D
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
7 a) Q$ P( t! o2 v摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心
8 p6 s7 U$ Q* c' a0 @7 t; @: I. J# E
妇科肿瘤 Gynecologic Cancer $ J. N3 j. a7 z, e" ^9 ?) O
摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院 " H( z) z! r5 {4 W" f
头颈肿瘤
- a- [. d5 y9 ^( M( E2 d( ^ Head and Neck Cancer + k+ M3 N) v5 p% x
摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心
- R5 N6 d0 i- i. F: P
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心 7 I& M: J+ G. W1 y
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心 1 d, X$ P) {% ?8 z
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
) N0 |( j0 k$ Q) H, Z. K. s摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心 5 r5 k0 O M( m2 ?/ ^8 g
血液系统恶性肿瘤-浆细胞疾病. t' N5 }& [& O( Y7 d3 p
Hematologic Malignancies—Plasma Cell Dyscrasia - r! X5 N4 O# q7 @" W) p& I9 {
摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院
- e$ f+ V/ k3 h% |6 y7 {& u1 q
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤
9 n) o2 o2 t6 n- j1 }% E3 ~ Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
/ E# ?! M$ e7 k2 g# l摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院
5 C' Y/ d2 ~ i3 \# I
肺癌-转移性非小细胞肺癌
, ]/ M |0 r9 r# D0 W Lung Cancer—Non-Small Cell Metastatic 4 l, n( i0 ?1 g. i g( m+ ] \# G% F
摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院
& p0 D8 j3 D h( D# i
e1 F4 G0 t* S/ F5 ]9 z摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院 ' z+ I/ ` F) S- ?
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院 ' p2 ?9 j6 Z8 L% W' ]4 s/ H8 b
黑色素瘤/皮肤癌( p& B4 H* T S; `# p# P
Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院
1 U$ @$ Z/ v: `0 \2 X( R" C/ e
快速摘要报告0 ?' u: N/ c8 _* W6 f3 b* ?" ?
Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心 " G' S( C) k0 E( H
临床科学研讨会
. ~9 J6 G: H, N; s% W Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院
7 M u) _+ L: N% @8 A! v- z" \
9 x" p! [& V+ X" ~2 S6 t | 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
